TG Therapeutics TGTX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's financing cash flow?
- TG Therapeutics (TGTX) reported financing cash flow of $390.83M in Q1 2026.
- How has TG Therapeutics's financing cash flow changed year-over-year?
- TG Therapeutics's financing cash flow increased by 6504.9% year-over-year, from -$6.1M to $390.83M.
- What is the long-term trend for TG Therapeutics's financing cash flow?
- Over 3 years (2021 to 2025), TG Therapeutics's financing cash flow has grown at a 29.9% compound annual growth rate (CAGR), from $41.42M to -$90.79M.
- What does financing cash flow mean?
- The net amount of cash a company receives from or pays to its investors and creditors.
- How do you interpret financing cash flow?
- Positive values indicate net capital raising or debt issuance, while negative values suggest debt repayment or capital returned to shareholders.
- How does financing cash flow compare across companies?
- Varies significantly based on the company's growth stage and capital structure strategy.